Back profile

Nick is a partner at Kilburn & Strode and head of the firm’s Life Sciences & Chemistry group in London. Clients globally recognise him for his specialisation in the biosciences, with significant clients in the areas of biotechnology and medical devices. His expertise lies in immunotherapy (in particular, T cells and antibodies), RNA interference, nanotechnology, recombinant DNA technology, diagnostics and microparticle technology.
His passions include working with biotechnology companies to add value by building strong patent portfolios aligned to their strategic goals, designing and implementing patenting strategies and providing commercial and strategic advice on third party rights in due diligence exercises. Throughout his career, Nick has advised numerous clients from initial funding through to their eventual IPO.
Nick’s experience and success in prosecution and opposition at the European Patent Office means that he is often asked to deal with cutting edge and high profile cases. For example, he represented The Johns Hopkins University in the seminal case that set the 'plausibility' test for the circumstances in which data generated after the filing date can be used to support inventive step in a European patent (T1329/04), and fronts the effort to help secure European protection for Harvard College’s cutting-edge work on the CRISPR/Cas9 gene-editing system.
When not working with clients to develop and deliver their IP strategies, Nick is responsible for delivery of Life Sciences & Chemistry group’s strategic plan.

"Nick brings over three decades’ experience to his supervision of the practice, personally taking on work in biotech and medical devices. He is an astute operator in the field of immunology, especially the T-cell sphere. He acted for an anonymous entity to revoke Cellectis’s patent relating to CAR T cells for allogeneic transplantation. " - IAM Patent 1000, 2023

"Lee heads the team and works with both biotechnology and medical devices clients, bringing specific expertise in the T cell niche." - IAM Patent 1000, 2022 

'Recommended' in IAM Patent 1000, 2021 

2022, 2021, 2020, 2016, 2015 and 2014 IP Stars Handbook, Managing IP – ‘IP Star’

2019: The Legal 500 for his work representing Harvard College in its European patent for its gene editing technology CRISPR.

2019:  IAM Patent – "a biosciences buff whose EPO advocacy in complex nanotechnology, immunology and diagnostics matters has to be seen to be believed."
2019, 2018 and 2015: Who’s Who Legal: Patents – a World leading patent attorney who "has a 'high profile' in the European patent market, say sources, and is commended for his expertise when it comes to the biotechnology and medical devices sectors" and 'First choice' Nick Lee primarily focuses his practice on prosecution and opposition matters at the European Patent Office, and specializes in the fields of biosciences.
2017: IAM Patent – for his work "fronting the effort to help se-cure protection for Harvard College’s cutting-edge work on the CRISPR/Cas9 gene-editing system".
2016: IAM Patent 1000 – handling of "all worldwide patent drafting and prosecution for bio-tech titan Immunocore’ and his work protecting a multi-purpose platform for using the body’s own defences to target cancer cells".


European Patent Attorney
Chartered UK Patent Attorney
IP Litigator - Patent
Representative before the Unified Patent Court (UPC) (2023)
BSc Hons (Biochemistry) - University of Bristol


​Chartered Institute of Patent Attorneys (CIPA)
The Institute of Professional Representatives before the European Patent Office (EPI)